Cubist Systematic Strategies LLC Has $663,000 Position in Verve Therapeutics, Inc. (NASDAQ:VERV)

Cubist Systematic Strategies LLC lowered its stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 82.7% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 117,600 shares of the company's stock after selling 561,025 shares during the period. Cubist Systematic Strategies LLC owned approximately 0.14% of Verve Therapeutics worth $663,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. BVF Inc. IL raised its position in shares of Verve Therapeutics by 962.2% during the fourth quarter. BVF Inc. IL now owns 6,904,050 shares of the company's stock valued at $38,939,000 after buying an additional 6,254,050 shares during the last quarter. Balyasny Asset Management L.P. raised its position in shares of Verve Therapeutics by 100.7% during the fourth quarter. Balyasny Asset Management L.P. now owns 85,116 shares of the company's stock valued at $480,000 after buying an additional 42,701 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in shares of Verve Therapeutics during the fourth quarter valued at about $50,000. Ameriprise Financial Inc. raised its position in shares of Verve Therapeutics by 14.5% during the fourth quarter. Ameriprise Financial Inc. now owns 258,873 shares of the company's stock valued at $1,460,000 after buying an additional 32,817 shares during the last quarter. Finally, Acuta Capital Partners LLC raised its position in shares of Verve Therapeutics by 9.7% during the fourth quarter. Acuta Capital Partners LLC now owns 160,200 shares of the company's stock valued at $904,000 after buying an additional 14,100 shares during the last quarter. Institutional investors and hedge funds own 97.11% of the company's stock.

Analyst Ratings Changes

Several research analysts recently issued reports on VERV shares. Cantor Fitzgerald raised shares of Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Tuesday, April 15th. William Blair reissued an "outperform" rating on shares of Verve Therapeutics in a research report on Friday, February 21st. Canaccord Genuity Group increased their price target on shares of Verve Therapeutics from $32.00 to $39.00 and gave the stock a "buy" rating in a research report on Tuesday, April 15th. HC Wainwright increased their price target on shares of Verve Therapeutics from $15.00 to $25.00 and gave the stock a "buy" rating in a research report on Monday, April 14th. Finally, Guggenheim increased their price target on shares of Verve Therapeutics from $18.00 to $24.00 and gave the stock a "buy" rating in a research report on Tuesday, April 15th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Verve Therapeutics has a consensus rating of "Buy" and an average target price of $25.75.

Verve Therapeutics Trading Up 0.2%

NASDAQ VERV opened at $4.32 on Friday. The firm has a market cap of $385.10 million, a price-to-earnings ratio of -1.76 and a beta of 1.82. The company has a 50 day moving average of $4.82 and a 200-day moving average of $5.87. Verve Therapeutics, Inc. has a 1-year low of $2.86 and a 1-year high of $9.31.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.36. The company had revenue of $32.98 million during the quarter, compared to analyst estimates of $7.13 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. On average, analysts forecast that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.

Want to see what other hedge funds are holding VERV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.